Clinical Trial

The Canadian Maraviroc Randomized Controlled Trial To Augment Rehabilitation Outcomes After Stroke

Study acronym: CAMAROS
Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 9, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The CAMAROS trial is a randomized controlled phase II trial analyzing the effect of coupling a C-C chemokine receptor 5 (CCR5) antagonist, Maraviroc (Celsentri), and exercise to improve both upper and lower extremity recovery after a stroke.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT04789616
Lead Sponsor University of Calgary
Collaborators: University Health Network, Toronto, University of California, Los Angeles, Sunnybrook Health Sciences Centre, University of British Columbia, Memorial University of Newfoundland, Dalhousie University, Parkwood Hospital, London, Ontario, Riverview Health Centre Foundation, The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Conditions Stroke
Enrollment 120 participants
Start Date 2022-09-15
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2024-07-09